Fusion-derived epithelial cancer cells express hematopoietic markers and contribute to stem cell and migratory phenotype in ovarian carcinoma

Cancer Research

Volumn 73, Issue 17, 2013, Pages 5360-5370

  Ramakrishnan, Mallika ^a   Mathur, Sandeep R ^b   Mukhopadhyay, Asok ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER CELL; CANCER STEM CELL; CELL FUSION; CELL INTERACTION; CELL MIGRATION; EPITHELIUM CELL; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LUNG CARCINOMA; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; CELL FUSION; CELL LINEAGE; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL12; CHEMOTAXIS; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, INBRED C57BL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84883475455     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0896     Document Type: Article

References (43)

1. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
2. Barker N, Clevers H. Tumor environment: a potent driving force in colorectal cancer? Trends Mol Med 2001;7:535-37. (Pubitemid 33127135)
3. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013;152:25-38.
4. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013; 23:93-106.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
6. Liu C, Chen Z, Zhang T, Lu Y. Multiple tumor types may originate from bone marrow-derived cells. Neoplasia 2006;8:716-24.
7. Avital I, Moreira AL, Klimstra DS, Leversha M, Papadopoulos EB, Brennan M, et al. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007;25:2903-09. (Pubitemid 350127875)
8. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-71. (Pubitemid 39564955)
9. Larizza L, Schirrmacher V, Pfluger E. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage. J Exp Med 1984;160:1579-84. (Pubitemid 15220784)
10. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, et al. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci U S A 2006;103:6321-25.
11. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, et al. Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res 2011;71:1497-505.
12. Cho KR, Shih LM. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
13. Weiss L, Ward PM. Lymphogenous and hematogenous metastasis of Lewis lung carcinoma in the mouse. Int J Cancer 1987;40:570-74. (Pubitemid 17148748)
14. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004;35:1014-21. (Pubitemid 39037185)
15. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-20.
16. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-18.
17. Suratt BT, Petty JM, Young SK, Malcolm KC, Lieber JG, Nick JA, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004;104:565-71. (Pubitemid 38900043)
18. Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, et al. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells 2007;25:1881-87. (Pubitemid 47258166)
19. Hu YX, Luo Y, Tan YM, Shi JM, Sheng LX, Fu HR, et al. Donor bone marrow-derived stem cells contribute to oral squamous cell carcinoma transformation in a recipient after hematopoietic stem cell transplantation. Stem Cells Dev 2012;21:177-80.
20. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91. (Pubitemid 30214011)
21. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904. (Pubitemid 39383039)
22. Josso N, di Clemente N, Gouedard L. Anti-Mullerian hormone and its receptors. Mol Cell Endocrinol 2001;179:25-32.
23. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. Syncytin is involved in breast cancer-endothelial cell fusions. Cell Mol Life Sci 2006;63:1906-11.
24. Vignery A. Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J Exp Pathol 2000;81:291-304. (Pubitemid 32061649)
25. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-24.
26. Yilmaz Y, Lazova R, Qumsiyeh M, Cooper D, Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant 2005;35:1021-24. (Pubitemid 40711841)
27. Placencio VR, Li X, Sherrill TP, Fritz G, Bhowmick NA. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS ONE 2010;5:e12920.
28. Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG. Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene 2001;20:7085-95. (Pubitemid 33052200)
29. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63. (Pubitemid 38428686)
30. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011;108:7547-52.
31. Takizawa H, Regoes RR, Boddupalli CS, Bonhoeffer S, Manz MG. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J Exp Med 2011;208:273-84.
32. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996;87:1-13. (Pubitemid 26018389)
33. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12. (Pubitemid 28007217)
34. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
35. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 2010;70:388-97.
36. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005;309:1369-73. (Pubitemid 41209363)
37. Pawelek JM. Tumor-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005;6:988-93. (Pubitemid 41685232)
38. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008;68:650-56. (Pubitemid 351206739)
39. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1a/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-99. (Pubitemid 350209982)
40. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003;22:8093-101. (Pubitemid 37487300)
41. Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, et al. The peritoneal tumor microenvironment of high-grade serous ovarian cancer. J Pathol 2012;227:136-45.
42. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004;4:901-09. (Pubitemid 39472956)
43. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113:4341-51.